Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Dear F.W.: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope ...

Subsequent annual testing has shown little to no progression. I take levothyroxine, Eliquis, verapamil and pravastatin. I’ve had it with pills. — F.W. ANSWER: In general, I recommend against stopping ...

Subsequent annual testing has shown little to no progression. I take levothyroxine, Eliquis, verapamil and pravastatin. I’ve ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...